Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer.
The post Cancer Drug Startup Antares Unveils $177M to Pick Up Where Scorpion Therapeutics Left Off appeared first on MedCity News.
